>>> GOGO - almost flat : FAA clears Gogo's next generation in-flight internet te

GOGO : FAA clears Gogo's next generation in-flight internet technology 

Received the final Supplemental Type Certificate (STC) from the FAA required to launch Gogo's 2Ku next generation satellite connectivity service. The technology is currently installed on Gogo's 737-500 test plane and is now cleared for in-flight testing. Gogo expects to launch commercial service of its 2Ku technology later this year.

Seven commercial airlines have signed up for either a trial or fleet deployment of 2Ku covering more than 500 commercial aircraft. Gogo expects to launch commercial service later this year and begin rapid installation of the backlog of 500 aircraft in 2016.

2Ku is expected to deliver peak speeds of more than 70 Mbps to the aircraft, which is more than 20 times the bandwidth provided by Gogo's first generation Air to Ground solution in the U.S. More information about this technology can be found here. - Source TradeTheNews.com

(BI) Gilead $140 Billion Spending Power Could Allow Bristol-Myers Buy


Gilead $140 Billion Spending Power Could Allow Bristol-Myers Buy
2015-08-24 14:36:57.649 GMT

BI BIOT GLOB SBKEYS
The largest M&A target for Gilead suggested in a recent BI survey
was Bristol-Myers Squibb, which is within reach. Gilead may be
able to push for a 4x debt-to-Ebitda ratio to borrow another $72
billion. Assuming cash funding of 50%, this gives Gilead $140
billion in spending power, making Bristol-Myers's $100 billion
enterprise value an easy reach, even with a 30% premium.
Bristol-Myers's 33x forward P/E may mean such a premium is
unnecessary. The question is whether Gilead has an appetite for
such a deal.

|0|0|567848|234538944|MMDL 235295986|MMDL 235295986|

This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Aug/24/2015 14:36 GMT

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: MOBI -12%, TOUR -5.6%

M&A news: SO -1.6% (acquiring GAS)

Select fan favorites showing weakness: FIT -14.5%, SHAK -13.6%, CYBR -13.5%, GPRO -11.9%, SWKS -11.9%, FEYE -11.5%, NFLX -10.1%, MBLY -9.1%, SBUX -7.5%, PANW -7.5%, SUNE -7.3%, TSLA -7.1%, TWTR -7.1%, AAPL -6.5%
Select China related names showing weakness after Shanhai was down 8.5% overnight: NQ -21%, BTU -18.5%, QIHU -16%, SFUN -14.1%, WBAI -12.9%, CSIQ -11.8%, JD -10.2%, BITA -9.6%, BABA -9.1%, CHL -8.5%, SPWR -8.3%, MGM -8.2%, WUBA -8.1%, SINA -8.1%
Select metals/mining stocks trading lower: CLF -11.2%, FCX -7.8%, X -7%, BHP -5.9%, MT -5.7%
Select oil/gas related names showing early weakness: PACD -12.3%, PBR -9.5%, LINE -5.4%, HAL -5.3%

Other news: VTL -80.8% (nnounces that topline results of its VTI-208 trial fail to achieve primary or secondary endpoints of improvement in overall survival; ), NBG -13.5% (cont uncertainty in Greece after snap elections called), DGLY -10.5% (Bloomberg reports that Sony (SNE) is considering entering drone market), RAD -9.7% (still checking), ESLT -7% (still checking, but was awarded $27 million contract to supply command and control and artillery systems to an Asia-Pacific Country), HLT -6.1% (still checking), GALE -5.2% (announce?s that the Independent Data Monitoring Committee has recommended to GALE that it can reduce the cardiac toxicity monitoring for patients in its NeuVax Phase 3 PRESENT clinical trial), CIE -3.3% (to sell its 40% participating interest in Blocks 21/09 and 20/11 offshore Angola for $1.75 bln to Empresa Pública), ALKS -1.7% (announces that FDA has advised it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia)

Analyst comments: WLL -10.7% (downgraded to Neutral at BofA/Merrill ), SPLK -8.3% (downgraded to Hold at Summit Research), GM -6.8% (resumed with a Underweight at Morgan Stanley), MRO -6.7% (downgraded to Neutral at BofA/Merrill ), KGC -1.9% (downgraded to Underperform at RBC Capital Mkts)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: N/A.

M&A news: GAS +7.3% (Southern Company (SO) to Acquire AGL Resources (GAS) in $12 Billion Transaction -- AGL Resources' shareholders will be entitled to receive $66 in cash)

Other news: SPEX +22.5% (provided an update on its case involving the company's NNPT subsidiary against Huawei), OPXA +15.7% (cont strength from last week), PPHM +7% (Peregrine Pharma and AstraZeneca (AZN) form collaboration to focus on on immuno-oncology combination clinical trial), ACTS +3.1% (Action Semi to purchase for cash up to 48,000,000 of its issued and outstanding ordinary shares through a Dutch Auction Tender Offer), JOE +2.1% (tenders offer to purchase up to 16,666,666 shares of its outstanding common stock at a price of $18.00 per share), EPZM +1.1% (FDA has accepted the company's investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients), .

Analyst comments: N/
A

Reuters - Heineken eyes controlling stake in India's United Breweries

Aug 24 Heineken NV, the world's third-largest brewer, is seeking to raise its stake in India's United Breweries Ltd to gain full management control as it bets on the country's growing thirst for beer, sources with direct knowledge of the matter said.

The Dutch brewer, the single largest shareholder in United Breweries with a 42.07 percent stake, plans to take that holding beyond 50 percent by buying shares from liquor baron Vijay Mallya and his group firms, the sources said.

The stake hike, a bet on one of the world's fastest growing beer markets, will be completed in a phased manner over the next couple of years, said the two sources, who declined to be named as the talks are private.

A spokeswoman for Heineken in Amsterdam declined to comment. A spokesman for UB Group, Mallya's group holding company, said that there had been no discussions on a stake sale in United Breweries.

>>> US Early premarket gappers

Gapping up: OPXA +15.7%, CIE +3.6%, PPHM +2.6%, GALE +1.5%, JOE +0.7%

Gapping down: WBAI -12.9%, NBG -12.8%, PACD -12.3%, CYBR -11.5%, FIT -10.6%, HLT -10.2%, LINE -10%, SFUN -9.6%, IBN -8.7%, TTM -8.6%, BITA -8.5%, MBLY -8.3%, WUBA -8.1%, CSIQ -8.1%, SPWR -7.8%, GPRO -7.6%, TSLA -7.6%, SUNE -7.3%, CHL -7.3%, ESLT -7%, BABA -6.9%, JD -6.8%, SWKS -6.4%, NFLX -6.4%, GM -5.7%, TWTR -5.6%, FEYE -5.5%, HAL -5.2%, SUBX -5.2%, MGM -5.1%, FCX -5%, BHP -4.7%, PANW -4.4%, X -4.4%, MT -4%

FT : Africa private equity group raises $1.4bn to invest in continent

--> Africa still represent more than 20% of Bollore Revenue, Bollore just announced a new rail project for 1bil this morning, we could contiue to see some devent outperformance of Sub saharian investments even if oil continue to trade lower and there is some geopolitical risks.

Bollore is down 20% since highs and weakness in emerging market could spur new investment in Africa...


FT : Africa private equity group raises $1.4bn to invest in continent 4.10 /4.30 appear to be a good level.

Abraaj Group, a Dubai-based company, has amassed the largest pool of private equity capital yet for investments across Africa.
The group, which focuses on private equity in emerging markets “beyond the Brics”, said it had raised $375m for a fund that will focus on North Africa.

Combined with capital raised in April targeted at the sub-Saharan region, the two funds give Abraaj just under $1.4bn to spend in the continent’s markets, a record sum to raise in a single year.
This follows an Africa-wide fund raised earlier this year by Helios Investment Partners, a rival to Abraaj, which was the first dedicated to the region to surpass $1bn.
The dawn of billion-dollar African private equity funds reflects a search by investors for higher returns than are on offer in the saturated buyout markets of the US and Europe, and also represents a bet on the continent’s growing middle class.
International buyout groups including Carlyle and KKR expanded into the region last year, with maiden investments often focused on consumer growth. This is despite concerns that larger funds in Africa could be left to chase relatively few opportunities, given the limited size of its capital markets.
Mustafa Abdel-Wadood, a partner at Abraaj who runs its regional funds, said that splitting the funds’ capital between north and south would give investors a choice over which markets they wanted to invest in.
“If they want to look at Africa as one continent, or they want to see it as separate markets, they can,” he said.
Mr Abdel-Wadood added that the funds would draw from an on-the-ground search for companies, as deals placed in the market are only a “subset” of opportunities. These are businesses we approach proactively,” he said.
Abraaj has already made six investments from the new North Africa fund, including a hospital group which it plans to roll out across the region.
The fund will look for majority or minority stakes in mid-market companies based in Algeria, Egypt, Morocco and Tunisia that Abraaj could help turn into regional market leaders.
Sharp falls in African currencies triggered by collapsing commodity prices have also posed pitfalls for private equity investors in the region.
Currency volatility had become a “big part of the discussion we’re having” over investments in the region, Mr Abdel-Wadood said.
“This is not the first time these markets have faced currency issues,” he added, noting that a drop in exchange rates often occurs in one big step. “Over the lifetime of an investment, this can be absorbed by the underlying growth of the business.”
Abraaj was, however, looking at defensive sectors more. “This is a year where one needs to be cautious,” Mr Abdel-Wadood said.